undefined undefined undefined

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

Event: ESC Congress 2025

Topic: Clinical

Session: Pharmacotherapy to improve outcomes in coronary disease

Access

Like

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1

Access

Like

Assessment of cardiovascular disease risk using different thresholds to define high risk on the pooled cohort equations

Event: ESC Congress 2018

Topic: Cardiovascular Epidemiology

Session: Atrial fibrillation, stroke and cardiovascular risk

Access

Like

Residual risk following myocardial infarction despite intensive medical management

Event: ESC Congress 2018

Topic: Cardiovascular Pharmacotherapy, Other

Session: Antiplatelet and anticoagulant drugs

Access

Like

Panel discussion and Q&A - Cardiovascular risk: the dangers of blood pressure and low-density lipoprotein cholesterol.

Event: ESC Congress 2017

Topic: Risk scores

Session: Cardiovascular risk: the dangers of blood pressure and low-density lipoprotein cholesterol

Access

Like

The burden of hypertension and high cholesterol – Impact of non-compliance and failure to reach goals.

Event: ESC Congress 2017

Topic: Risk scores

Session: Cardiovascular risk: the dangers of blood pressure and low-density lipoprotein cholesterol

Access

Like

Adherence to intensive medical management in the year following hospitalization for myocardial infarction

Event: ESC Congress 2017

Topic: Epidemiology, lipids

Session: Prevention - Epidemiology

Access

Like

Statin use among HIV-infected adults by cardiovascular disease risk status

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Lipid-lowering therapy: old faces and new issues

Access

Like

Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes

Event: ESC Congress 2016

Topic: Epidemiology, lipids

Session: Are we ever going to get to lipid goals?

Access

Like

Increased recurrent coronary heart disease and mortality risk among intensive medically managed patients following myocardial infarction

Event: ESC Congress 2016

Topic: Epidemiology, lipids

Session: The wide world of cardiovascular research and practice

Access

Like

undefined undefined undefined

Contributor content

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Assessment of cardiovascular disease risk using different thresholds to define high risk on the pooled cohort equations

Residual risk following myocardial infarction despite intensive medical management

Panel discussion and Q&A - Cardiovascular risk: the dangers of blood pressure and low-density lipoprotein cholesterol.

The burden of hypertension and high cholesterol – Impact of non-compliance and failure to reach goals.

Adherence to intensive medical management in the year following hospitalization for myocardial infarction

Statin use among HIV-infected adults by cardiovascular disease risk status

Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes

Increased recurrent coronary heart disease and mortality risk among intensive medically managed patients following myocardial infarction

ESC 365 is supported by